

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4)

Maha Hussain, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: June 2, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to new drug application (NDA) 21-986, proposed trade name Sprycel (dasatinib) tablets (BMS-354825), sponsored by Bristol Myers Squibb, with the proposed indications for (1) treatment of adults with chronic, accelerated, or blast phase chronic myeloid leukemia with resistance to prior therapy including imatinib, and (2) the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia and lymphoid blast chronic myeloid leukemia with resistance or intolerance to prior therapy, I am eligible to receive waivers under 18 U.S.C. §208 (b)(3) and 21 U.S.C. §355 (n)(4).

| Type of Interest | Nature | Magnitude |
|-------------------------|-------------------|--|
| Stock | 2 competing firms | Valued at less than \$5,001 per firm. |
| Stock | 2 competing firms | Valued between \$5,001 and \$25,000 per firm. |
| Stock | 2 competing firms | Valued between \$25,001 and \$50,000 per firm. |

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

/s/
Signature of SGE

4-18-06
Date